A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

Inclusion Criteria: * Male or female ≥20 and ≤60 years of age * In good health as determined by medical history, physical examination, and clinical judgment of the investigator * Willing and able to comply with all required study visits and follow-up required by this protocol * Must provide written informed consent Exclusion Criteria: * Known or potential exposure to avian influenza virus or any H5N1 HA antigen vaccine * Had any influenza vaccine within 6 months * Administered with any vaccine within 30 days * A history of hypersensitivity to vaccines or inflammatory or degenerative neurological disease * Receiving chronic administration of immunosuppressants or other immune-modifying drugs within 6 months * Known HIV, hepatitis B (HBsAg) or hepatitis C seropositivity * Any medical illness including clinically significant acute pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests * Receiving immunoglobulins and/or any blood products within the three months * Acute disease at the time of enrolment * Psychiatric, addictive, or any disorder, which may compromise the ability to give a truly informed consent for participation of this study or adequate compliance * Breast feeding or pregnant women